CC9815B3-88D0-4376-B96F-B979E1FBD0C7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.337713534822601
- age_years
- 67
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.674
- INTERFERON_GAMMA_RESPONSE+0.594
- MYC_TARGETS_V1+0.539
- OXIDATIVE_PHOSPHORYLATION+0.531
- E2F_TARGETS+0.526
- MYC_TARGETS_V2+0.508
- MTORC1_SIGNALING+0.497
- ANGIOGENESIS+0.490
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.478
- DNA_REPAIR+0.467
Top 10 suppressed
- KRAS_SIGNALING_DN-0.361
- SPERMATOGENESIS-0.257
- HEDGEHOG_SIGNALING-0.243
- PANCREAS_BETA_CELLS-0.164
- ESTROGEN_RESPONSE_EARLY-0.142
- UV_RESPONSE_DN-0.122
- APICAL_SURFACE-0.094
- WNT_BETA_CATENIN_SIGNALING-0.086
- MYOGENESIS-0.083
- MITOTIC_SPINDLE-0.063
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | EC1C727A-1F71-4C09-B867-7F163424D463 | — | — | 0.972 |
| 2 | SRR934883 | — | — | 0.971 |
| 3 | AB5294B5-4A59-493A-9016-C2778735745F | — | — | 0.966 |
| 4 | 4A54E284-9902-4E4C-A5BC-1BF144106EA3 | — | — | 0.966 |
| 5 | 6410821A-1C6A-4F64-939F-196313B8F1E5 | — | — | 0.965 |
| 6 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.963 |
| 7 | 9BB56866-4E99-4E8A-A63F-2D4801558F14 | — | — | 0.962 |
| 8 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.961 |
| 9 | E7BE221B-273D-4C04-BE79-366E6455EFBC | — | — | 0.961 |
| 10 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.959 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.674 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.594 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.539 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.531 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.526 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.508 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.497 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.478 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.467 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.457 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.449 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.435 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.424 | Inavolisib | — uncovered |
| APOPTOSIS | 0.412 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.408 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.407 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.402 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.388 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.354 | Inavolisib | — uncovered |